Vantage Investment Advisors’s Edwards Lifesciences EW Stock Holding History

Vantage Investment Advisors’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-48	Closed	-$1K	–	773
2016 Q4	$1K	Buy	+48	New	+$1.55K	﹤0.01%	748
2016 Q2	–	Sell	-120	Closed	-$4K	–	861
2016 Q1	$4K	Sell	120 -480	-80%	-$13.2K	﹤0.01%	646
2015 Q4	$16K	Hold	600	–	–	0.01%	425
2015 Q3	$14K	Buy	600 +480	+400%	+$11.6K	0.01%	428
2015 Q2	$3K	Sell	120 -120	-50%	-$2.71K	﹤0.01%	653
2015 Q1	$6K	Buy	240 +120	+100%	+$2.69K	﹤0.01%	672
2014 Q4	$3K	Hold	120	–	–	﹤0.01%	658
2014 Q3	$2K	Hold	120	–	–	﹤0.01%	648
2014 Q2	$2K	Hold	120	–	–	﹤0.01%	647
2014 Q1	$1K	Hold	120	–	–	﹤0.01%	633
2013 Q4	$1K	Buy	+120	New	+$1.35K	﹤0.01%	610

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Winslow Capital Management Minneapolis, Minnesota $29.1B AUM 43.86% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vantage Investment Advisors's EW Position: Q1 2017 in Review

Vantage Investment Advisors sold out of Edwards Lifesciences (EW) in Q1 2017, closing a stake of 48 shares — an estimated $1K sold.

Vantage Investment Advisors first reported a position in EW in Q4 2013 and held it in 11 quarters. The position peaked at $16K in Q4 2015. 691 funds tracked by Wall St. Rank hold EW as of Q1 2017.

Vantage Investment Advisors reported no remaining Edwards Lifesciences position as of Q1 2017 after selling out during the quarter.
Vantage Investment Advisors sold 48 Edwards Lifesciences shares in Q1 2017, an estimated $1K.
Vantage Investment Advisors first reported a position in Edwards Lifesciences in Q4 2013 and held it in 11 quarters.
Vantage Investment Advisors's Edwards Lifesciences position peaked at $16K in Q4 2015.
691 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2017.

Based on Vantage Investment Advisors's 13F filing for Q1 2017, filed 12 May 2017.